BioSpace News Archive

Policy

LADAVRU® NEWS “HOVERINK BIOTECHNOLOGIES SEEKS COMMERCIAL PARTNERING OPPORTUNITIES IN ONCOLOGY SUPPORTIVE THERAPIES AND SEEKS A COMMERCIALIZATION AGREEMENT FOR ITS INVESTIGATIONAL DRUG LADAVRU®”

HOVERINK BIOTECHNOLOGIES, seeks to enter into a licensing agreement for the exclusive rights to commercialize LADAVRU(TM) (Dronabinol for injection) and an oral formulation of LADAVRU®.

July 5, 2018
·
5 min read
Deals

Xtant Medical Holdings, Inc. Announces Expiration of Rights Offering

XtantTM Medical Holdings, Inc. announces that the subscription period for its previously announced rights offering of shares of the Company’s common stock at a subscription price of $7.20 per share expired on June 18, 2018, and these rights are no longer exercisable.

July 5, 2018
·
4 min read
Business

Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony

Cocrystal Pharma, Inc. announced that Dr. Gary Wilcox, Vice Chairman and Chief Executive Officer of Cocrystal, will ring the Nasdaq Stock Market Closing Bell on Wednesday, June 6, 2018.

July 5, 2018
·
5 min read
Business

FDS, Inc. Announces New CEO

FDS, Inc. announced the appointment of Adam McMullin as Chief Executive Officer (CEO)

July 5, 2018
·
2 min read
Drug Development

Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder

First patient enrolled in the ASCEND study

July 5, 2018
·
6 min read
Policy

Nu-Med Plus Inc. applies for Innovative Patent on Reactive Tube Coating

Nu-Med Plus, Inc. announced its patent filing for its pioneering chemically reactive coating.

July 5, 2018
·
2 min read
Pharm Country

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease

Cognition Therapeutics, Inc. announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812)

July 5, 2018
·
5 min read
Deals

Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

Madrigal Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $200 million of its common stock.

July 5, 2018
·
3 min read
Business

Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors

Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND

July 5, 2018
·
5 min read
Business

Laurie Heilmann Named President of New CrownBio Global Life Science and Diagnostic Solutions Division

Crown Bioscience announces the appointment of Laurie Heilmann as President of CrownBio Global Life Science Product and Diagnostic Solutions.

July 5, 2018
·
2 min read